IRCCS Centro Neurolesi Bonino Pulejo
irccsme.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
66
Active
26
Phase 3
0
Total enrollment
6,489
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| bioactivated GRA for adult patients | — | — | — | — | — | 1 | |
| bioactivated GRA for pediatric patients | — | — | — | — | — | 1 |
Next readouts
- 2026-05-19
Top conditions
- Parkinson Disease11
- Multiple Sclerosis8
- Stroke8
- Autism Spectrum Disorder5
- Dementia3
- Mild Cognitive Impairment (MCI)3
- Alzheimer Disease3
- Neurologic Disorder3
Frequently asked questions about IRCCS Centro Neurolesi Bonino Pulejo
- How many clinical trials does IRCCS Centro Neurolesi Bonino Pulejo have on ClinicalTrials.gov?
- IRCCS Centro Neurolesi Bonino Pulejo is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of IRCCS Centro Neurolesi Bonino Pulejo's trials are in Phase 3?
- 0 of IRCCS Centro Neurolesi Bonino Pulejo's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does IRCCS Centro Neurolesi Bonino Pulejo focus on?
- IRCCS Centro Neurolesi Bonino Pulejo's most-studied conditions on ClinicalTrials.gov are Parkinson Disease, Multiple Sclerosis, Stroke, Autism Spectrum Disorder, Dementia.
- When are IRCCS Centro Neurolesi Bonino Pulejo's next clinical trial readouts?
- IRCCS Centro Neurolesi Bonino Pulejo has 1 upcoming primary-completion readout tracked here; the soonest is “Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)”, expected around 2026-05-19.